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Abstracts / Biol Blood Marrow Transplant 19 (2013) S257eS278 S265correlation with ICU admission, in-hospital death or death
within one year of transplant. Most stress test parameters
correlate poorly with outcomes of HSCT. Routine stress
testing is unlikely to be of significant prognostic value. Stress
echocardiogram is of somewhat more value than stress
MUGA given that rest LVEF and exercise time correlate with
in-hospital death, but a standardized evaluation of exercise
capacity in the clinic and rest echo may be adequate sub-
stitutes.307
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Introduction: Busulfan (bu) is one of the most used
chemotherapy in conditioning regimens for patients
submitted to hematopoietic cell transplantation (HCT). As Bu
pharmacokinetic (PK) is widely variable, dose adjustment
according to patient PK has been shown to minimize toxic-
ities improving clinical outcome. Usually, PK is calculated
from blood samples collected after the first Bu dose, guiding
adjustment of following doses. Although this method has
shown to be reliable, it can be difficult to perform PK in an
optimal time frame. Therefore, using a test dose before HCT
can optimize this method, potentially given more accurate
dose adjustment. Bu test dose has been used with Bu iv
formulation, but little is knownwith oral Bu. In countries like
Brazil where oral Bu is still been used because of cost issues
an optimal drug administration should be developed.
Objectives: To validate the use of oral Bu test dose by
comparing PK from dose test and first conditioning regimen
dose.
Methods: 19 patientes were enrolled. Median age was 28
year (range, 4-56). 4 (21%) patients received autologous HCT
while 19 (79%) allogeneic grafts from MRD or MUD donors.
As conditioning regimens, 1 patient recieved Bu(16)/
Flu(160), 9 Bu(16)/Cy(120), 3 Bu(16)Mel(140), 2 Bu(12)/
Cy(120)/Mel(140) and 4 Bu(12)/Cy(120)/Etoposide(1200).
After oral test dose (1mg/kg) 72 hours before conditioning
regimen, blood samples were collected at 8 time points.
Samples were also collected after the first Bu dose (1mg/kg)
during conditioning regimen. Bu concentrations were
measured by HPLC. PK parameters were estimated by using
nonlinear mixed effects model computer program. No Bu
dose adjustment was performed based on test dose.Results: PK parameters were comparable between test dose
and first conditioning dose: median Bu Clearance (microMol/
min) was 10115,9 (range: 333,43-18270,4) and 11866,1
(range: 4520,3-15589,2) respectively (P ¼ 0,738); median
concentration steady state (mcg/L) was 0,80 (range: 0,55-
1,59) and 0,76 (range: 0,59-1,23) respectively (P ¼ 0,672);
half life (hours) was 2,85 (range: 1,65-5,61) and 2,65 (range:
1,71-6,09) respectively (P ¼ 0,172). Area under the curve
(AUC) (mcgMol.min) was also comparable showing amedian
of 1174 (range: 799-2328) and 1110 (range: 857-1795)
respectively (P ¼ 0,679). Toxicities was comparable to liter-
ature data: 14 (88%) and 5 (12%) patients developed grades 1
to 3 and grade 4 mucositis respectively; 2 (10%) patients
developed sinuisodal obstruction syndrome (SOS) both
received Bu/Cy/Etoposide protocol. All patients achieved full
donor chimerism. Incidence of grade II-IV acute and exten-
sive chronic GVHD was 55% and 31% respectively. With
a median follow-up of 82 days (range: 18-321) 17 patients
were alive.
Conclusions: A population PK model for oral Bu could be
developed, showing efficacy and safety of oral Bu test dose.308
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Background: Intravenous catheters are widely used in
hematopoietic stem cell transplant (HSCT) patients.
Complications associated with these catheters are frequently
encountered and contribute to morbidity, mortality, and
increased cost of treatment. Studies exploring such compli-
cations in this unique patient population are lacking. We
retrospectively studied infectious and thrombotic catheter-
related complications in acute myeloid leukemia (AML)
patients after undergoing HSCT at the largest tertiary referral
center in Oklahoma.
Methods: AML patients above the age of 18 who had HSCT at
The University of Oklahoma Health Sciences Center between
January, 2000 and June, 2012 were identified and medical
records were reviewed. Patients were stratified according to
age, first HSCT type and type of catheter(s) present at or after
the first HSCT (Hickman, peripherally inserted central cath-
eter (PICC) or infusion port (IP)). First blood stream infection
(BSI) and deep venous thrombosis (DVT) events after the first
HSCT were reported (subsequent events were not included).
Statistical analysis was performed using SAS 9.2 software
(SAS Institute Inc.). Fisher's exact test was used to compare
patients in the different groups.
Results: 62 patients were included. Median age at diagnosis
was 44 years. 42 (68%) were males and 20 (32%) were
females. 53 (87%) were White, 4 (7%) Native American and 3
(5%) African American. 26 (43%) had sibling (SIB), 22 (36%)
unrelated donor (URD) and 13 (21%) double cord blood (DCB)
transplant. 56 (93%) had Hickman, 30 (50%) PICC and 7 (12%)
IP. 28 patients had one catheter type only (24 Hickman and 4
PICC). BSI occurred in 37% of all cases. BSI rates according to
the presence or absence of a particular catheter type were
38% vs. 33% for Hickman, 37% vs. 38% for PICC and 43% vs. 36%
for IP. In patients with only one catheter type, BSI rates were
38% for Hickman vs. 50% for PICC (P¼ .9). BSI occurred in 40%
